Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase VII results from ECHO-202/KEYNOTE-037.

被引：35
|
作者：
Hamid, Omid
Bauer, Todd Michael
Spira, Alexander I.
Olszanski, Anthony J.
Patel, Sandip Pravin
Wasser, Jeffrey S.
Smith, David C.
Balmanoukian, Ani Sarkis
Aggarwal, Charu
Schmidt, Emmett V.
Zhao, Yufan
Gowda, Hema
Gangadhar, Tara C.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.6010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6010
引用
收藏
页数：6
相关论文
共 50 条
  • [11] Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
    Powderly, John D.
    Klempner, Samuel J.
    Naing, Aung
    Bendell, Johanna
    Garrido-Laguna, Ignacio
    Catenacci, Daniel V. T.
    Taylor, Matthew H.
    Lee, James J.
    Zheng, Fred
    Zhou, Feng
    Gong, Xiaohua
    Gowda, Hema
    Beatty, Gregory L.
    ONCOLOGIST, 2022, 27 (11): : 905 - E848
  • [12] Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
    Long, Georgina V.
    Dummer, Reinhard
    Hamid, Omid
    Gajewski, Thomas
    Caglevic, Christian
    Dalle, Stephane
    Arance, Ana
    Carlino, Matteo S.
    Grob, Jean-Jacques
    Kim, Tae Min
    Demidov, Lev V.
    Robert, Caroline
    Larkin, James M. G.
    Anderson, James
    Maleski, Janet E.
    Jones, Mark M.
    Diede, Scott J.
    Mitchell, Tara C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [13] Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
    Long, Georgina, V
    Dummer, Reinhard
    Humid, Omid
    Gajewski, Thomas F.
    Caglevic, Christian
    Dalle, Stephan
    Arance, Ana
    Carlino, Matteo S.
    Grob, Jean-Jacques
    Kim, Tae Min
    Demidov, Lev
    Robert, Caroline
    Larkin, James
    Anderson, James R.
    Maleski, Janet
    Jones, Mark
    Diede, Scott J.
    Mitchell, Tara C.
    LANCET ONCOLOGY, 2019, 20 (08): : 1083 - 1097
  • [14] Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
    Necchi, Andrea
    van der Heijden, Michiel S.
    Trukhin, Dmytro
    Peer, Avivit
    Gurney, Howard
    Alekseev, Boris Y.
    Parnis, Francis X.
    Leibowitz, Raya
    De Santis, Maria
    Grivas, Petros
    Clark, Jason
    Munteanu, Mihaela
    Kataria, Ritesh
    Jia, Calvin
    Balar, Arjun V.
    de Wit, Ronald
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [15] Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.
    Perez, Raymond P.
    Riese, Matthew John
    Lewis, Karl D.
    Saleh, Mansoor N.
    Daud, Adil
    Berlin, Jordan
    Lee, James J.
    Mukhopadhyay, Sutapa
    Zhou, Li
    Serbest, Gul
    Hamid, Omid
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [16] Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
    Cho, Byoung Chul
    Brana, Irene
    Cirauqui, Beatriz
    Aksoy, Sercan
    Couture, Felix
    Hong, Ruey-Long
    Miller Jr, Wilson H.
    Chaves-Conde, Manuel
    Teixeira, Margarida
    Leopold, Lance
    Munteanu, Mihaela
    Ge, Joy Yang
    Swaby, Ramona F.
    Hughes, Brett G. M.
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [17] A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.
    Cohen, Ezra E. W.
    Rischin, Danny
    Pfister, David G.
    Vermorken, Jan Baptist
    Zhao, Yufan
    Gowda, Hema
    Ge, Joy Yang
    Jin, Fan
    Harrington, Kevin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [18] Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study
    Hansen, A.
    Massard, C.
    Ott, P. A.
    Haas, N.
    Lopez, J.
    Ejadi, S.
    Wallmark, J.
    Keam, B.
    Delord, J-P.
    Aggarwal, R.
    Gould, M.
    Qiu, P.
    Saraf, S.
    Keefe, S.
    Piha-Paul, S. A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [19] Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
    Naing, Aung
    Powderly, John D.
    Falchook, Gerald
    Creelan, Benjamin
    Nemunaitis, John
    Lutzky, Jose
    Diab, Adi
    Wang, Judy S.
    Laing, Naomi
    Niewood, Michelle
    Gong, Xiaohua
    Zhou, Gongfu
    Patel, Manish
    CANCER RESEARCH, 2018, 78 (13)
  • [20] The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)
    Doi, Toshihiko
    Fujiwara, Yutaka
    Shitara, Kohei
    Shimizu, Toshio
    Yonemori, Kan
    Matsubara, Nobuaki
    Ohno, Izumi
    Kogawa, Takahiro
    Naito, Yoichi
    Leopold, Lance
    Munteanu, Mihaela
    Yatsuzuka, Naoyoshi
    Han, Shi Rong
    Samkari, Ayman
    Yamamoto, Noboru
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 152 - 162
12345